ABIOMED, Inc. (NASDAQ:ABMD) gets downgraded to Neutral by BTIG Research

ME Staff
-
0

Analyst Ratings For ABIOMED, Inc. (NASDAQ:ABMD)

Today, ABIOMED, Inc. (NASDAQ:ABMD) stock was downgraded by BTIG Research from Buy to Neutral.

There are 2 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on ABIOMED, Inc. (NASDAQ:ABMD) is Buy with a consensus target price of $400.3333 per share, a potential 98.39% upside.

Some recent analyst ratings include

  • 8/1/2019-ABIOMED, Inc. (NASDAQ:ABMD) gets downgraded to Neutral by BTIG Research
  • 5/3/2019-ABIOMED, Inc. (NASDAQ:ABMD) had its Buy rating reiterated by SunTrust Banks with a $340.00 price target
  • 4/4/2018-ABIOMED, Inc. (NASDAQ:ABMD) has coverage initiated with a Buy ➝ Buy rating and $332.00 price target
  • On 5/8/2019 Martin P Sutter, Director, sold 4,664 with an average share price of $259.97 per share and the total transaction amounting to $1,212,500.08.
  • On 2/15/2019 Martin P Sutter, Director, sold 20,000 with an average share price of $360.16 per share and the total transaction amounting to $7,203,200.00.
  • On 2/13/2019 Martin P Sutter, Director, sold 5,000 with an average share price of $360.00 per share and the total transaction amounting to $1,800,000.00.
  • On 2/6/2019 Martin P Sutter, Director, sold 5,985 with an average share price of $349.49 per share and the total transaction amounting to $2,091,697.65.
  • On 2/4/2019 Martin P Sutter, Director, sold 19,943 with an average share price of $350.28 per share and the total transaction amounting to $6,985,634.04.
  • On 1/25/2019 David M Weber, COO, sold 24,000 with an average share price of $351.47 per share and the total transaction amounting to $8,435,280.00.
  • On 9/25/2018 Michael G Howley, VP, sold 10,000 with an average share price of $432.50 per share and the total transaction amounting to $4,325,000.00.

About ABIOMED, Inc. (NASDAQ:ABMD)
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. Read More…

Recent Trading Activity for ABIOMED, Inc. (NASDAQ:ABMD)
Shares of ABIOMED, Inc. closed the previous trading session at 202.21 −76.35 27.41% with shares trading hands.